UNI-494

About Unicycive Therapeutics

Unicycive Therapeutics is an agile, clinical-stage biotech focused exclusively on developing innovative therapies for kidney disease. Its strategy centers on in-licensing or acquiring promising, overlooked assets and advancing them with speed and operational efficiency. The company's lead asset, Oxylanthanum Carbonate (OLC), has an FDA PDUFA date of June 29, 2026, positioning it for a potential near-term commercial launch in the multi-billion dollar hyperphosphatemia market.

Therapeutic Areas